Rocket One RKTO
NASDAQ RKTO
$0.67 -0.03 (-4.40%)
At close: Sep 9, 2026 · 4:00 PM EDT

Rocket One (RKTO) Non-Current Deferred Tax Liability (2022)

Rocket One's (RKTO) quarterly Non-Current Deferred Tax Liability came in at $1.2 million in Q4 2022.

Analysis

Rocket One (RKTO) Non-Current Deferred Tax Liability (2022) Analysis & Trends

Rocket One has disclosed Non-Current Deferred Tax Liability across 1 years of filings, most recently posting $1.2 million for Q4 2022.

  • In Q4 2022, Non-Current Deferred Tax Liability changed N/A year-over-year to $1.2 million; the TTM figure through Dec 2022 stood at $1.2 million (changed N/A YoY), while the FY2022 annual figure was $1.2 million, changed N/A from the prior year.
  • Non-Current Deferred Tax Liability came in at $1.2 million for Q4 2022 at Rocket One.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $1.2 million in Q4 2022 to a low of $1.2 million in Q4 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn
10 Rocket One 13.86 Mn 5.97 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 1.20 Mn